Nycomed has agreed to market Roche osteoporosis medication Bonviva in key Asia-Pacific markets.

The company will initially market the drug in China, Hong King, Malaysia, Australia, New Zealand, the Philippines, Singapore, Taiwan and Vietnam, with possible future options to commercialise the drug in additional countries.

Nycomed will become marketing authorisation holder in all the licensed territories.

Bonviva is a bisphosphonate used to treat osteoporosis in postmenopausal women.